Journal
ZEITSCHRIFT FUR GASTROENTEROLOGIE
Volume 61, Issue 1, Pages 71-75Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1952-1233
Keywords
HCC; immunotherapy; biomarkers
Categories
Ask authors/readers for more resources
Immunotherapy has shown promising efficacy in late-line treatment of advanced HCC, even in fourth-line scenarios. Established biomarkers predicting response to immunotherapy were not detected in this case, but mutations in SETD2 and LRP1B genes may explain the exceptional response.
Immunotherapy has become the standard of care in advanced HCC but is only approved in first- or second-line treatment. We report a patient with HCC refractory to several lines of tyrosine kinase inhibitors, who was treated with Ipilimumab and Nivolumab (Ipi/Nivo) as the fourth line. The tumor responded profoundly to Ipi/Nivo. Established biomarker-predicting responses to immunotherapy, such as a high PD-L1 staining, a high combined-positive score, microsatellite instability or a high tumor mutational burden, were not detected. Potential negative predictive markers for response to immunotherapy such as CTNNB1 and TERT were present. This constellation puts the spotlight on two mutations observed here in the SET domain-containing 2 (SETD2) and low-density lipoprotein receptor-related protein 1b (LRP1B) genes, which may explain the outstanding response. Our case demonstrates that immunotherapy can be efficient in a late-line scenario, resulting in long-term survival. Further studies should prospectively evaluate the value of SETD2 and LRP1B alterations as predictors for the success of immunotherapy in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available